Literature DB >> 32047762

Treating BRAFV600E metastatic colorectal patients in 2019: a BEACON of hope?

Christelle de la Fouchardiere1.   

Abstract

Entities:  

Year:  2019        PMID: 32047762      PMCID: PMC7011598          DOI: 10.21037/atm.2019.08.110

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  20 in total

1.  Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients.

Authors:  Christelle de la Fouchardière; Romain Cohen; David Malka; Rosine Guimbaud; Héloïse Bourien; Astrid Lièvre; Wulfran Cacheux; Pascal Artru; Eric François; Marine Gilabert; Emmanuelle Samalin-Scalzi; Aziz Zaanan; Vincent Hautefeuille; Benoit Rousseau; Hélène Senellart; Romain Coriat; Ronan Flippot; Françoise Desseigne; Audrey Lardy-Cleaud; David Tougeron
Journal:  Oncologist       Date:  2019-05-31

2.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

3.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Authors:  Michael J Overman; Sara Lonardi; Ka Yeung Mark Wong; Heinz-Josef Lenz; Fabio Gelsomino; Massimo Aglietta; Michael A Morse; Eric Van Cutsem; Ray McDermott; Andrew Hill; Michael B Sawyer; Alain Hendlisz; Bart Neyns; Magali Svrcek; Rebecca A Moss; Jean-Marie Ledeine; Z Alexander Cao; Shital Kamble; Scott Kopetz; Thierry André
Journal:  J Clin Oncol       Date:  2018-01-20       Impact factor: 44.544

Review 4.  Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

Authors:  Filippo Pietrantonio; Fausto Petrelli; Andrea Coinu; Maria Di Bartolomeo; Karen Borgonovo; Claudia Maggi; Mary Cabiddu; Roberto Iacovelli; Ilaria Bossi; Veronica Lonati; Mara Ghilardi; Filippo de Braud; Sandro Barni
Journal:  Eur J Cancer       Date:  2015-02-09       Impact factor: 9.162

5.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Authors:  Chiara Cremolini; Fotios Loupakis; Carlotta Antoniotti; Cristiana Lupi; Elisa Sensi; Sara Lonardi; Silvia Mezi; Gianluca Tomasello; Monica Ronzoni; Alberto Zaniboni; Giuseppe Tonini; Chiara Carlomagno; Giacomo Allegrini; Silvana Chiara; Mauro D'Amico; Cristina Granetto; Marina Cazzaniga; Luca Boni; Gabriella Fontanini; Alfredo Falcone
Journal:  Lancet Oncol       Date:  2015-08-31       Impact factor: 41.316

6.  NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

Authors:  Al B Benson; Alan P Venook; Mahmoud M Al-Hawary; Lynette Cederquist; Yi-Jen Chen; Kristen K Ciombor; Stacey Cohen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Ignacio Garrido-Laguna; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Jeffrey Meyerhardt; Eric D Miller; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Evan Wuthrick; Kristina M Gregory; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2018-04       Impact factor: 11.908

7.  FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.

Authors:  F Loupakis; C Cremolini; L Salvatore; G Masi; E Sensi; M Schirripa; A Michelucci; E Pfanner; I Brunetti; C Lupi; C Antoniotti; F Bergamo; S Lonardi; V Zagonel; P Simi; G Fontanini; A Falcone
Journal:  Eur J Cancer       Date:  2013-10-15       Impact factor: 9.162

8.  Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients.

Authors:  Johan Gagnière; Aurélien Dupré; Sepideh S Gholami; Denis Pezet; Thomas Boerner; Mithat Gönen; Thomas P Kingham; Peter J Allen; Vinod P Balachandran; Ronald P De Matteo; Jeffrey A Drebin; Rona Yaeger; Nancy E Kemeny; William R Jarnagin; Michael I D'Angelica
Journal:  Ann Surg       Date:  2020-01       Impact factor: 12.969

9.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Authors:  Federica Di Nicolantonio; Miriam Martini; Francesca Molinari; Andrea Sartore-Bianchi; Sabrina Arena; Piercarlo Saletti; Sara De Dosso; Luca Mazzucchelli; Milo Frattini; Salvatore Siena; Alberto Bardelli
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

10.  Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

Authors:  Scott Kopetz; Jayesh Desai; Emily Chan; Joel Randolph Hecht; Peter J O'Dwyer; Dipen Maru; Van Morris; Filip Janku; Arvind Dasari; Woonbook Chung; Jean-Pierre J Issa; Peter Gibbs; Brian James; Garth Powis; Keith B Nolop; Suman Bhattacharya; Leonard Saltz
Journal:  J Clin Oncol       Date:  2015-10-12       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.